<?xml version="1.0" encoding="UTF-8"?>
<p>Disease activity for participants with DLE or SCLE was evaluated using Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI)
 <xref rid="R41" ref-type="bibr">41</xref> and a Physician Global Assessment. Procedure-related adverse events (AEs) and serious AEs were monitored and recorded.
</p>
